Adjunctive corticosteroid therapy in pediatric severe sepsis: Observations from the RESOLVE study*
Authors:
- Jerry J. ZimmermanJZJerry J. Zimmerman
- Mark D. WilliamsMWMark D. Williams
- 1 January 2011
- journal article
- research article
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 12 (1) , 2-8
Abstract
To assess whether corticosteroids, used as adjunctive therapy for pediatric severe sepsis, is associated with improved outcomes. Retrospective cohort study examining the clinical database derived from the RESOLVE (REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspective, F1K-MC-EVBP) trial of activated protein C for pediatric severe sepsis. A total of 104 pediatric centers in 18 countries from which data were originally gathered. Children with severe sepsis (n = 477), requiring both vasoactive-inotropic infusions and mechanical ventilation. Within this cohort, 193 children received corticosteroids during their septic episode and 284 did not. None. Baseline summary characteristics demonstrated that children receiving or not receiving corticosteroids had similar demographics and disease severity as indicated by age, gender, mean Pediatric Risk of Mortality scores, and mean number of organ dysfunctions. Use of adjunctive corticosteroids increased during the F1K-MC-EVBP trial. Indications for corticosteroid prescription were therapeutic (89%, mostly shock) and prophylactic (13%). All cause 28-day mortality among children receiving and not receiving corticosteroids was 15.1% and 18.8%, respectively, p = .30. There was no difference in mean vasoactive-inotropic infusion days between the corticosteroid and no corticosteroid groups, 4.5 days vs. 4.3 days, respectively, p = .59. Similarly there was no difference in mean ventilator days between the corticosteroid and no corticosteroid groups, 8.3 days vs. 7.7 days, respectively, p = .38. Children with severe sepsis who received adjunctive corticosteroid therapy exhibited similar illness severity compared with those who did not. No definitive improvement in outcomes can be attributable to adjunctive corticosteroid therapy in the largest pediatric sepsis trial conducted to date.Keywords
This publication has 54 references indexed in Scilit:
- Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine*Critical Care Medicine, 2009
- Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008Critical Care Medicine, 2008
- Intensive Insulin Therapy in the Medical ICUNew England Journal of Medicine, 2006
- Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome*Critical Care Medicine, 2006
- Persistent hyperglycemia in critically ill childrenThe Journal of Pediatrics, 2005
- Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock*Critical Care Medicine, 2004
- The Hypothalamic–Pituitary–Adrenal Axis and Immune-Mediated InflammationNew England Journal of Medicine, 1995
- Assessing the outcome of pediatric intensive careThe Journal of Pediatrics, 1992
- Stimulation of Muscle Protein Degradation and Prostaglandin E2Release by Leukocytic Pyrogen (Interleukin-1)New England Journal of Medicine, 1983
- Muscle Proteolysis Induced by a Circulating Peptide in Patients with Sepsis or TraumaNew England Journal of Medicine, 1983